07:00 , Apr 10, 2000 |  BioCentury  |  Finance

A Bloody Mary hits the spot

President Clinton's belated mea culpa for the genomics blow-off, followed by Celera's news that it had completed the genome of a single person, provided the hangover remedy that brought investors bellying back up to the...
07:00 , Apr 6, 2000 |  BC Extra  |  Financial News

Ista files for IPO

Ista Pharmaceuticals (formerly Advanced Corneal Systems) filed to raise up to $86.25 million in an IPO. The offering will be underwritten by CIBC World Markets; ING Barings; and Prudential Vector Healthcare. Ista (Irvine, Calif.) is...
08:00 , Jan 4, 2000 |  BioCentury  |  Finance

1999 Financial Markets Review: Out with the old

Mergers and acquisitions finally had a significant impact on the biotech sector last year, as for the first time in the history of the group a meaningful number of public companies disappeared. Those companies are...
08:00 , Mar 10, 1999 |  BC Week In Review  |  Clinical News

Vitrase enzyme injection: Began Phase II testing

Advanced Corneal Systems Inc., Irvine, Calif.   Product: Vitrase enzyme injection   Use: Stop vitreal hemorrhage, in diabetics, after trauma, and in macular degeneration   Status: Advanced Corneal Systems began Phase II testing to evaluate safety and...
08:00 , Dec 7, 1998 |  BC Week In Review  |  Clinical News

Vitrase enzyme injection: Advanced Corneal began U.S. Phase III testing in 800 patients

The product is approved in Mexico. Advanced Corneal Systems Inc., Irvine, Calif.   Product: Vitrase enzyme injection   Indication: Clear vitreous hemorrhage   Status: Advanced Corneal began U.S. Phase III testing in 800 patients, with evaluation...
08:00 , Nov 23, 1998 |  BC Week In Review  |  Clinical News

Advanced Corneal regulatory update

Mexico granted marketing approval for Advanced Corneal's Vitrase, an injectable enzyme that induces the clearing of vitreous hemorrhage. Vitrase will be distributed in Mexico by Sophia Laboratories S.A. de C.V. (Guadalajara, Mexico). Advanced Corneal...
08:00 , Nov 16, 1998 |  BC Week In Review  |  Clinical News

Vitrase enzyme injection: Phase II

Advanced Corneal reported that Phase II findings showed tolerability over two months in 153 patients, 84 percent of whom are diabetic. Three doses were tested as a single injection into the vitreous cavity of the...
07:00 , Oct 19, 1998 |  BC Week In Review  |  Clinical News

Advanced Corneal regulatory update

The FDA granted fast track designation to Advanced Corneal's Vitrase enzyme injection to treat vitreous hemorrhage in the back of the eye. Vitrase is in a U.S. Phase II trial, and the company said...
07:00 , Jul 13, 1998 |  BC Week In Review  |  Company News

Advanced Corneal management update

Advanced Corneal Systems Inc., Irvine, Calif.   Business: Ophthalmic   Hired: J.C. MacRae as VP and CFO, formerly VP and CFO of Imagyn Medical Inc.   ...
07:00 , Jun 29, 1998 |  BC Week In Review  |  Clinical News

Vitrase enzyme injection: Phase III

Advanced Corneal presented final data from its 225-patient Phase III dose response trial of Vitrase in Mexico. Patients experiencing vitreous hemorrhage for a minimum of one month received a single injection of 7.5, 37.5 or...